AI assistant
Sending…
SELLAS Life Sciences Group, Inc. — Director's Dealing 2014
Jan 23, 2014
33651_dirs_2014-01-22_3f840640-959e-4e93-b263-5c33588a8fc9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2013-12-31
Reporting Person: SCHWARTZ MARK W. (EVP & Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-12-31 | Common Stock | J | 5656 | $1.8785 | Acquired | 509665 | Direct |
Footnotes
F1: Pursuant to the Issuer's Employee Stock Purchase Plan.
More from SELLAS Life Sciences Group, Inc.
Regulatory Filings
2026
Jun 2
Regulatory Filings
2026
May 12
Interim / Quarterly Report
2026
May 12
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 20
Major Shareholding Notification
2026
Jan 30
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9